Form 4: KalVista CEO Sells Shares for Tax Obligations

KalVista Pharmaceuticals' CEO, Benjamin L. Palleiko, sold 7,294 shares of common stock at $15.84 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Benjamin L. Palleiko, KalVista Pharmaceuticals' Director and Chief Executive Officer, acquired 15,625 shares of common stock on September 6, 2025, through the conversion of Restricted Stock Units (RSUs).
• Following this acquisition, Palleiko beneficially owned 402,483 shares of common stock directly.
• On September 8, 2025, Palleiko disposed of 7,294 shares of common stock at a price of $15.84 per share.
• This sale was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations arising from the vesting and settlement of RSUs, not a discretionary transaction.
• After the sale, Palleiko's direct beneficial ownership of common stock stands at 395,189 shares.
• Each RSU represents a contingent right to receive one share of common stock upon settlement for no consideration.
• The RSUs vest quarterly, with 1/16th of the total number of shares vesting on each quarterly anniversary of the Vesting Commencement Date, which began on June 6, 2024, subject to continued service.

Sentiment

Score: 5

Explanation: The filing reports a routine 'sell to cover' transaction by an executive to meet tax obligations from RSU vesting. This is a neutral event and does not indicate positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

The filing does not contain any forward-looking statements or guidance beyond the vesting schedule of the RSUs.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This transaction is a routine insider filing (Form 4) for a pharmaceutical company executive, reflecting standard compensation practices involving equity awards and subsequent tax obligations. It does not provide insights into broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The transaction is a routine 'sell to cover' for tax purposes and is unlikely to have a significant impact on the company's stock price or long-term shareholder value. It reflects standard executive compensation practices.
• Employees: The RSU vesting and subsequent tax-related sale are part of the company's equity compensation program, which is a common practice to incentivize and retain key personnel.

Next Steps

• Continued vesting of remaining Restricted Stock Units on a quarterly basis, subject to continued service.

Key Dates

Recommendation

This Form 4 filing details a non-discretionary 'sell to cover' transaction by the CEO to satisfy tax obligations arising from RSU vesting. Such transactions are routine and do not reflect a change in the executive's confidence in the company or its future prospects. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

KalVista Pharmaceuticals, KALV, Benjamin L. Palleiko, CEO, Director, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, Tax Withholding, Sell to Cover